Sign up to create alerts for Instruments,
Economic Events and content by followed authors
Free Sign Up Already have an account? Sign In
0.915
+0.015
+1.67%
Quotes
All Instrument Types
- All Instrument Types
- Indices
- Equities
- ETFs
- Funds
- Commodities
- Currencies
- Crypto
- Bonds
- Certificates
Please try another search
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance Find Stocks Now
Mesoblast Ltd (MSB)
Sydney
| Symbol | Exchange | Currency | ||
|---|---|---|---|---|
| MSB | Sydney | AUD | Delayed | |
| MESO | NASDAQ | USD | Real-time | |
| MEOBF | OTC Markets | USD | Delayed |
Add to/Remove from a Portfolio
Add to Watchlist
- Closed. Currency in AUD ( Disclaimer )
- Volume: 6,794,624
- Bid/Ask: 0.910 / 0.920
- Day's Range: 0.890 - 0.935
Mesoblast
0.915
+0.015
+1.67%
- General
- Chart
- News & Analysis
- Financials
- Technical
- Forum
- Financial Summary
- Income Statement
- Balance Sheet
- Cash Flow
- Ratios
- Dividends
- Earnings
MSB Income Statement
Featured here, the Income Statement (earnings report) for Mesoblast Ltd, showing the company's financial performance from operating and non operating activities such as revenue, expenses and income for the last 4 periods (either quarterly or annually).
Advanced Income Statement 
| Period Ending: | 2023 31/12 |
2023 30/09 |
2023 30/06 |
2023 31/03 |
||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 1.69 | 1.69 | 2.14 | 1.94 | ||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||
| Cost of Revenue, Total | 9.7 | 9.7 | 15.42 | 13.31 | ||||||||||||||||||||||||||||||
| Gross Profit | -8 | -8 | -13.28 | -11.37 | ||||||||||||||||||||||||||||||
| Total Operating Expenses | 14.99 | 14.99 | 21.22 | 16.32 | ||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||
| Operating Income | -13.29 | -13.29 | -19.08 | -14.38 | ||||||||||||||||||||||||||||||
| Interest Income (Expense), Net Non-Operating | - | - | - | - | ||||||||||||||||||||||||||||||
| Gain (Loss) on Sale of Assets | - | - | - | - | ||||||||||||||||||||||||||||||
| Other, Net | 3.03 | 3.03 | 2.88 | 4.27 | ||||||||||||||||||||||||||||||
| Net Income Before Taxes | -16.32 | -16.32 | -21.96 | -18.65 | ||||||||||||||||||||||||||||||
| Provision for Income Taxes | -0.051 | -0.051 | -0.04 | -0.046 | ||||||||||||||||||||||||||||||
| Net Income After Taxes | -16.27 | -16.27 | -21.92 | -18.6 | ||||||||||||||||||||||||||||||
| Minority Interest | - | - | - | - | ||||||||||||||||||||||||||||||
| Equity In Affiliates | - | - | - | - | ||||||||||||||||||||||||||||||
| U.S GAAP Adjustment | - | - | - | - | ||||||||||||||||||||||||||||||
| Net Income Before Extraordinary Items | -16.27 | -16.27 | -21.92 | -18.6 | ||||||||||||||||||||||||||||||
| Total Extraordinary Items | - | - | - | - | ||||||||||||||||||||||||||||||
| Net Income | -16.27 | -16.27 | -21.92 | -18.6 | ||||||||||||||||||||||||||||||
| Total Adjustments to Net Income | - | - | - | - | ||||||||||||||||||||||||||||||
| Income Available to Common Excluding Extraordinary Items | -16.27 | -16.27 | -21.92 | -18.6 | ||||||||||||||||||||||||||||||
| Dilution Adjustment | -0.007 | -0.007 | 0.032 | 0.035 | ||||||||||||||||||||||||||||||
| Diluted Net Income | -16.26 | -16.26 | -21.95 | -18.64 | ||||||||||||||||||||||||||||||
| Diluted Weighted Average Shares | 851.46 | 851.46 | 787.23 | 736.58 | ||||||||||||||||||||||||||||||
| Diluted EPS Excluding Extraordinary Items | -0.019 | -0.019 | -0.028 | -0.025 | ||||||||||||||||||||||||||||||
| DPS - Common Stock Primary Issue | - | - | - | - | ||||||||||||||||||||||||||||||
| Diluted Normalized EPS | -0.012 | -0.012 | -0.019 | -0.017 | ||||||||||||||||||||||||||||||
* In Millions of USD (except for per share items)
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on the income statement, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Write your thoughts about Mesoblast Ltd
Are you sure you want to delete this chart?
Delete Cancel
Replace the attached chart with a new chart ?
Replace Cancel
Comment Guidelines
Harry Aus
Feb 26, 2024 8:44
I'm retaining msb will have an approval this year buy
0
0
Umar Ohiko
Jan 22, 2022 0:50
i don't understand anything here
0
0
Wisdom Anyang
Jun 08, 2021 5:14
am new an in I don't understand anything here
0
0
NSingh
Oct 19, 2020 15:36
just buy
0
2
Full Time Full Time
Oct 19, 2020 9:48
what is the update for MSB? Buy, Hold or Sell?
0
0
Full Time Full Time
Oct 19, 2020 9:48
what is the update for MSB? Buy, Hold or Sell?
0
0
David E Youssef
Oct 05, 2020 16:44
Watch the sellout tomorrow
1
0
Poe Kae
Oct 02, 2020 22:02
in my opinion msb will recover quite quickly from current share price. its a lot happening in US including th election. I would be worry if this is the only product they have inline but they have other products which are currently in stage 3 and some will soon be going for fda approval." be greedy when others are fearful " warren buffett
4
4
David E Youssef
Oct 02, 2020 22:02
It has been a on indicative sell for the lst few weeksAfter that hitThe indicators and MA will promote a further sellThere may be bullish rally due to the fact of how cheap it is since it hasnt dropped this low since 2016But that wont last long as there will be drastic pullback till they prove the product and build investor confident back up
3
1
Poe Kae
Oct 02, 2020 22:02
in my opinion msb will recover quite quickly from current share price. its a lot happening in US including th election. I would be worry if this is the only product they have inline but they have other products which are currently in stage 3 and some will soon be going for fda approval." be greedy when others are fearful " warren buffett
0
2
Asanka Asp
Oct 02, 2020 11:02
Buy or Sell?
0
2
Annie Weng
Oct 02, 2020 11:02
Buy
0
4
David E Youssef
Oct 02, 2020 11:02
Sell mate!It will take them a few months if that to prove the drug Coming close to the elections too
3
0
tu nguyen
Oct 02, 2020 11:02
if you think they have more ammo in the bank to prove themselves to the FDA - it's shopping time!
0
0
George SalmaS
Oct 02, 2020 11:02
Definitely sell, the sentiment is bearish. The share price will not bounce in the foreseeable future unless treatment efficacy is further substantiated & FDA approval is granted. There is a long way to go before this happens.
3
0
David E Youssef
Oct 02, 2020 11:02
George SalmaS totally agree, thats what i said. Absolute gamble if you buy, youre more likely to win against the casino than to make money on this share. A buy would be around the march low, $1 something
2
0
Add Chart to Comment
Confirm Block
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
Report this comment
I feel that this comment is:
Comment flagged
Thank You!
Your report has been sent to our moderators for review